Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.
Michael Mina, MD, PhD
Assistant Professor, Epidemiology & Immunology
Harvard T.H Chan School of Public Health
Associate Medical Director, Pathology
Brigham & Woman’s Hospital
Harvard Medical School
Onyema Ogbuagu, MD, FACP
Associate Professor of Medicine
Director, HIV Clinical Trials
Section of Infectious Diseases
Yale University School of Medicine
New Haven, Connecticut
Although much remains unknown about coronavirus disease 2019 (COVID-19), knowledge is expanding every hour, and many healthcare providers, overwhelmed by infected patients and a struggling healthcare infrastructure, are unable to keep up with the changing landscape. Furthermore, the lag in peer-reviewed publication timelines means that the most critical information, when not disseminated by the Centers for Disease Control and Prevention (CDC) or national and international organizations, will be distributed by mainstream media through social media platforms, interspersed with false, contradictory, or misleading information, thereby presenting additional time-consuming challenges to clinicians. The rapidly evolving nature of the pandemic necessitates the dissemination of up-to-date information through continuing education programs in order to ensure healthcare providers are optimally prepared to care for patients.
With cases of COVID-19 surpassing 51 million worldwide, the rush to develop a vaccine capable of slowing the pandemic and lessening the morbidity and mortality of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is underway. Several COVID-19 vaccines are now being studied in phase 3 trials, and clinicians would benefit from a review of these ongoing efforts, particularly the status of vaccines close to approval. This educational activity will provide clinicians a review of the Food and Drug Administration’s (FDA) guidance on vaccine approval and emergency use authorization (EUA), up-to-date safety and efficacy information on vaccine candidates in late-stage development, and steps to prioritize patients who would benefit most from vaccination once available. Alongside this knowledge, clinicians must be prepared to combat vaccine mistrust by educating patients on scientific concepts surrounding vaccination, such as herd immunity and safety data.
This program is intended for infectious disease experts, immunologists, geriatricians, primary care physicians, nurse practitioners, physician’s assistants, nurses, and other members of the healthcare team involved in, or interested in, education regarding COVID-19 vaccines.
Upon completion of this educational activity, participants should be able to:
There is no registration fee for participating in this activity. To register, click the registration buttons on this page or call Integrity Continuing Education, Inc. at 1-855-835-4004.
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Michael J. Mina, MD, PhD
Consulting Fees: Detect Diagnostics
Onyema Ogbuagu, MD, FACP
Consulting Fees: Gilead Sciences, ViiV
Speakers’ Bureaus: Gilead Sciences
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the view of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
On the day of the program, you may access the event by going to any of the following links:
There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 1.25 AMA PRA Category 1 CME credit(s)™. To do so, you must participate in the virtual livestream activity and complete the posttest and evaluation following the event. A statement of credit will be issued only upon submission of a completed activity evaluation form.